Journal for Immunotherapy of Cancer This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 13, 2019 Category: Cancer & Oncology Source Type: research

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
ConclusionThis study provides technical feasibility data for correlative studies. Tissue biopsies provide distinct data from the blood and may predict response to pembrolizumab. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 12, 2019 Category: Cancer & Oncology Source Type: research

Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
ConclusionWithin the limitations of humanized PD-X models, targeting CD277J by TEG001 is safe and efficient. Therefore, we have initiated clinical testing of TEG001 in a phase I first-in-human clinical trial (NTR6541; date of registration 25 July 2017). (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 11, 2019 Category: Cancer & Oncology Source Type: research

Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
ConclusionTargeting of CD39 by ASOs represents a promising state-of-the art therapeutic approach to improve immune responses against tumors. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 11, 2019 Category: Cancer & Oncology Source Type: research

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
ConclusionsThe data presented here indicate that a subset of FL patients, identified by certain KIRs/KIR-ligands, have improved outcome and may benefit from additional rituximab treatment. Taken together, this suggests that the efficacy of tumor-reactive mAb treatment for some patients is influenced by KIRs on NK cells. However, prior to considering these genotypes in a clinically-actionable manner, these findings need independent validation in other studies. (Source: Journal for Immunotherapy of Cancer)
Source: Journal for Immunotherapy of Cancer - March 11, 2019 Category: Cancer & Oncology Source Type: research